European Innovation Council

Innoventric is a medical device company based in Ness-Ziona, Israel, focused on developing innovative percutaneous solutions for Tricuspid Regurgitation and right heart disease. Founded in 2017, the company has made significant advancements with its proprietary Trillium™ technology, designed to treat Tricuspid Valve Regurgitation. Innoventric's device features a functional tricuspid valve replacement that employs cross-caval anchoring and a multi-valve design, aimed at enhancing blood flow regulation. The company has conducted over ten implantations of the Trillium™ technology as part of its first human clinical trial in Europe. Additionally, Innoventric maintains a comprehensive patent portfolio for the Trillium™ and related technologies, positioning itself as a key player in the structural heart medical device sector.

MediWound Ltd. is an integrated biopharmaceutical company based in Yavne, Israel, that specializes in developing, manufacturing, and commercializing innovative therapeutic products for severe burns and chronic wounds. Founded in 2000, the company is known for its flagship product, NexoBrid, which is an FDA-approved biopharmaceutical designed for the removal of eschar in adults with deep partial- and full-thickness thermal burns, offering a less invasive alternative to surgical interventions. MediWound also advances other product candidates, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic and hard-to-heal wounds, and MWPC003 for connective tissue disorders. The company aims to address significant unmet medical needs in these areas and improve patient outcomes.

MediWound Ltd. is an integrated biopharmaceutical company based in Yavne, Israel, that specializes in developing, manufacturing, and commercializing innovative therapeutic products for severe burns and chronic wounds. Founded in 2000, the company is known for its flagship product, NexoBrid, which is an FDA-approved biopharmaceutical designed for the removal of eschar in adults with deep partial- and full-thickness thermal burns, offering a less invasive alternative to surgical interventions. MediWound also advances other product candidates, including EscharEx, which has completed Phase II clinical trials for the debridement of chronic and hard-to-heal wounds, and MWPC003 for connective tissue disorders. The company aims to address significant unmet medical needs in these areas and improve patient outcomes.

RS Research is a clinical-stage biotechnology company based in Istanbul, Turkey, focused on developing innovative nanomedicines for cancer treatment. Founded in 2015, the company has established a proprietary drug delivery platform known as Sagitta®, which enhances the therapeutic index of its drug candidates. RS Research’s pipeline includes multiple proprietary programs at various stages of preclinical and clinical development, with its lead candidate, RS-0139, currently undergoing Phase I clinical trials in oncology patients. The company also offers a range of services, including preclinical absorption and metabolism assessments, bioanalytical testing, and patent consulting. Additionally, RS Research operates a GMP-certified production facility for the manufacture of clinical batch drug candidates and actively engages in co-development projects with international partners.

Nanoscent Ltd is an Israeli startup founded in 2017, specializing in the development of an IoT-based scent recognition platform that leverages innovative sensor technologies rooted in nanotechnology. The company focuses on monitoring and analyzing scent data across various sectors, including utilities for air and water pollution reporting, manufacturing for production quality control, automotive for cabin air quality management, and health management through the analysis of fecal scent data to identify health changes. Nanoscent's flagship product, VOCID® H2Confirm, is a sensor-based monitoring system designed for the hydrogen supply chain, enabling real-time monitoring of hydrogen purity and detecting impurities and volatile organic compounds. By providing timely alerts for contamination, Nanoscent enhances safety and efficiency across its targeted industries.

Restore Medical is a medical device company based in Or Yehuda, Israel, established in 2016. The company specializes in providing innovative treatment solutions for patients suffering from congestive heart failure. Its flagship product, ContraBand, is a catheter-delivered implant designed specifically for patients with left ventricle failure who have preserved right ventricle function. This device aims to enhance left ventricle ejection fraction, minimize mitral regurgitation, and restore optimal ventricular geometry. By addressing these critical issues, Restore Medical's technology seeks to significantly improve patient quality of life and decrease rates of hospital readmission.

Indoor Robotics Ltd, founded in 2018 and based in Ramat Gan, Israel, specializes in the design and development of Tando, an innovative AI-powered patrol drone tailored for indoor security and inspection tasks. The drone employs independent AI navigation and a patented unobtrusive ceiling docking system, providing real-time monitoring and predictive analysis to minimize false alarms. Tando's automated data collection and analysis capabilities ensure consistent quality, enhancing safety and security measures. By integrating robotics with advanced AI, Indoor Robotics aims to deliver efficient and cost-effective solutions for intelligent indoor monitoring. Collaborating with leaders in the security and smart building sectors, the company is at the forefront of transforming indoor surveillance and inspection through cutting-edge technology.

Colospan Ltd is a clinical-stage medical device company based in Kfar Saba, Israel, specializing in healthcare equipment for colorectal surgeries. Established in 2010, Colospan develops proprietary technology aimed at preventing anastomotic leaks and the need for diverting colonic stomas after intestinal surgeries. The company’s lead product is a single-use, temporary intraluminal bypass device designed to reduce contact between fecal matter and the anastomotic site, thereby mitigating the complications associated with such leaks. This innovative device is intended to prevent or delay the need for colostomy after surgeries performed for severe intestinal inflammatory diseases and colorectal cancer. Colospan’s technology seeks to enhance patient recovery by reducing the risk of life-threatening symptoms associated with clinical anastomotic leaks and minimizing post-operative complications, ultimately supporting the well-being of patients following significant surgical procedures.

Innoventric is a medical device company based in Ness-Ziona, Israel, focused on developing innovative percutaneous solutions for Tricuspid Regurgitation and right heart disease. Founded in 2017, the company has made significant advancements with its proprietary Trillium™ technology, designed to treat Tricuspid Valve Regurgitation. Innoventric's device features a functional tricuspid valve replacement that employs cross-caval anchoring and a multi-valve design, aimed at enhancing blood flow regulation. The company has conducted over ten implantations of the Trillium™ technology as part of its first human clinical trial in Europe. Additionally, Innoventric maintains a comprehensive patent portfolio for the Trillium™ and related technologies, positioning itself as a key player in the structural heart medical device sector.

Healium Medical Ltd is a medical technology company based in Yokneam Illit, Israel, founded in 2017. The company specializes in the development of a non-contact guided ultrasound ablation system aimed at treating atrial fibrillation. Its innovative technology features a miniature ultrasound transducer that enables contactless circumferential pulmonary vein isolation, offering real-time lesion monitoring capabilities. This system simplifies the procedural workflow, reduces procedure time, and enhances efficacy compared to traditional methods that require direct tissue contact and extensive catheter maneuvering. Healium Medical's solutions represent a significant advancement in the treatment of atrial fibrillation, aiming to improve patient outcomes and procedural efficiency.

Healium Medical Ltd is a medical technology company based in Yokneam Illit, Israel, founded in 2017. The company specializes in the development of a non-contact guided ultrasound ablation system aimed at treating atrial fibrillation. Its innovative technology features a miniature ultrasound transducer that enables contactless circumferential pulmonary vein isolation, offering real-time lesion monitoring capabilities. This system simplifies the procedural workflow, reduces procedure time, and enhances efficacy compared to traditional methods that require direct tissue contact and extensive catheter maneuvering. Healium Medical's solutions represent a significant advancement in the treatment of atrial fibrillation, aiming to improve patient outcomes and procedural efficiency.

PlasFree is a medical device company based in Nazareth, Israel, founded in 2017. It specializes in the development of ClearPlasma, a device designed to enhance the treatment of massive bleeding by modifying human plasma. ClearPlasma extracts fibrinolytic proteins, including pepsinogen, which are responsible for dissolving blood clots, and alters the plasma to improve its coagulation properties. The device can be integrated into conventional apheresis systems, allowing healthcare professionals to obtain blood and plasma products that are more effective in managing excessive bleeding. PlasFree aims to revolutionize treatment protocols for massive bleeding, ensuring safer and more efficient care worldwide.

PlasFree is a medical device company based in Nazareth, Israel, founded in 2017. It specializes in the development of ClearPlasma, a device designed to enhance the treatment of massive bleeding by modifying human plasma. ClearPlasma extracts fibrinolytic proteins, including pepsinogen, which are responsible for dissolving blood clots, and alters the plasma to improve its coagulation properties. The device can be integrated into conventional apheresis systems, allowing healthcare professionals to obtain blood and plasma products that are more effective in managing excessive bleeding. PlasFree aims to revolutionize treatment protocols for massive bleeding, ensuring safer and more efficient care worldwide.

Colospan Ltd is a clinical-stage medical device company based in Kfar Saba, Israel, specializing in healthcare equipment for colorectal surgeries. Established in 2010, Colospan develops proprietary technology aimed at preventing anastomotic leaks and the need for diverting colonic stomas after intestinal surgeries. The company’s lead product is a single-use, temporary intraluminal bypass device designed to reduce contact between fecal matter and the anastomotic site, thereby mitigating the complications associated with such leaks. This innovative device is intended to prevent or delay the need for colostomy after surgeries performed for severe intestinal inflammatory diseases and colorectal cancer. Colospan’s technology seeks to enhance patient recovery by reducing the risk of life-threatening symptoms associated with clinical anastomotic leaks and minimizing post-operative complications, ultimately supporting the well-being of patients following significant surgical procedures.

Indoor Robotics Ltd, founded in 2018 and based in Ramat Gan, Israel, specializes in the design and development of Tando, an innovative AI-powered patrol drone tailored for indoor security and inspection tasks. The drone employs independent AI navigation and a patented unobtrusive ceiling docking system, providing real-time monitoring and predictive analysis to minimize false alarms. Tando's automated data collection and analysis capabilities ensure consistent quality, enhancing safety and security measures. By integrating robotics with advanced AI, Indoor Robotics aims to deliver efficient and cost-effective solutions for intelligent indoor monitoring. Collaborating with leaders in the security and smart building sectors, the company is at the forefront of transforming indoor surveillance and inspection through cutting-edge technology.

Innoventric is a medical device company based in Ness-Ziona, Israel, focused on developing innovative percutaneous solutions for Tricuspid Regurgitation and right heart disease. Founded in 2017, the company has made significant advancements with its proprietary Trillium™ technology, designed to treat Tricuspid Valve Regurgitation. Innoventric's device features a functional tricuspid valve replacement that employs cross-caval anchoring and a multi-valve design, aimed at enhancing blood flow regulation. The company has conducted over ten implantations of the Trillium™ technology as part of its first human clinical trial in Europe. Additionally, Innoventric maintains a comprehensive patent portfolio for the Trillium™ and related technologies, positioning itself as a key player in the structural heart medical device sector.

Nanoscent Ltd is an Israeli startup founded in 2017, specializing in the development of an IoT-based scent recognition platform that leverages innovative sensor technologies rooted in nanotechnology. The company focuses on monitoring and analyzing scent data across various sectors, including utilities for air and water pollution reporting, manufacturing for production quality control, automotive for cabin air quality management, and health management through the analysis of fecal scent data to identify health changes. Nanoscent's flagship product, VOCID® H2Confirm, is a sensor-based monitoring system designed for the hydrogen supply chain, enabling real-time monitoring of hydrogen purity and detecting impurities and volatile organic compounds. By providing timely alerts for contamination, Nanoscent enhances safety and efficiency across its targeted industries.

HIL Applied Medical is developing a new class of ultra-compact, high-performance accelerators for proton therapy. HIL applies a patented approach to particle acceleration and beam delivery, combining nano-technology with ultra-high-intensity lasers and ultra-fast magnets. These technological breakthroughs enable meaningful reduction in the size, complexity and cost of proton therapy systems, without compromising clinical utility. Thus HIL aims to enable, for the first time, a single-room add-on proton therapy solution that is truly cost-effective. HIL Applied Medical is a privately-held company, backed by VCs and global strategic partners. It is headquartered in the High-Tech Park, Givat Ram, Jerusalem, Israel; and have a wholly-owned subsidiary in Reno, Nevada (United States).

Nanoscent Ltd is an Israeli startup founded in 2017, specializing in the development of an IoT-based scent recognition platform that leverages innovative sensor technologies rooted in nanotechnology. The company focuses on monitoring and analyzing scent data across various sectors, including utilities for air and water pollution reporting, manufacturing for production quality control, automotive for cabin air quality management, and health management through the analysis of fecal scent data to identify health changes. Nanoscent's flagship product, VOCID® H2Confirm, is a sensor-based monitoring system designed for the hydrogen supply chain, enabling real-time monitoring of hydrogen purity and detecting impurities and volatile organic compounds. By providing timely alerts for contamination, Nanoscent enhances safety and efficiency across its targeted industries.

Indoor Robotics Ltd, founded in 2018 and based in Ramat Gan, Israel, specializes in the design and development of Tando, an innovative AI-powered patrol drone tailored for indoor security and inspection tasks. The drone employs independent AI navigation and a patented unobtrusive ceiling docking system, providing real-time monitoring and predictive analysis to minimize false alarms. Tando's automated data collection and analysis capabilities ensure consistent quality, enhancing safety and security measures. By integrating robotics with advanced AI, Indoor Robotics aims to deliver efficient and cost-effective solutions for intelligent indoor monitoring. Collaborating with leaders in the security and smart building sectors, the company is at the forefront of transforming indoor surveillance and inspection through cutting-edge technology.

MeMed Diagnostics Ltd. is a personalized diagnostics company founded in 2009 and headquartered in Tirat Carmel, Israel. The company specializes in developing innovative diagnostic solutions to enhance patient care and reduce healthcare costs by providing rapid and actionable insights for infectious diseases. Its flagship product, MeMed BV, is a test designed to distinguish between bacterial and viral infections, while the ImmunoDx platform utilizes proprietary biomarkers and algorithms to analyze patients' immune responses, helping physicians make informed antibiotic treatment decisions. MeMed's technologies aim to mitigate the misuse of antibiotics, which is a significant issue globally, leading to ineffective treatments and the emergence of resistant bacterial strains. By addressing the diagnostic gaps in infectious disease management, MeMed seeks to improve clinical outcomes and promote the responsible use of antibiotics.

OncoHost is a clinical-stage biotechnology company based in Binyamina, Israel, focused on developing personalized strategies to enhance the efficacy of cancer therapies. Founded in 2017, the company leverages proprietary proteomic analysis to gain insights into individual patient responses to treatment, addressing the significant challenge of therapy resistance in oncology. By analyzing proteomic changes in blood samples, OncoHost's platform facilitates the early identification of patients likely to be non-responsive to cancer treatments and aids in discovering new drug targets. This innovative approach combines bioinformatics, systems biology, and machine learning to provide healthcare institutions with critical information regarding predicted clinical benefits from therapies, ultimately enabling the development of tailored treatment strategies that aim to improve patient outcomes and minimize side effects. Through extensive clinical programs in collaboration with leading academic and clinical partners, OncoHost positions itself at the forefront of precision cancer medicine.